Do symbiotic and vitamin e supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial

Journal of Research in Medical Sciences

Volumn 21, Issue 7, 2016, Pages

  Ekhlasi, Golnaz ^a   Mohammadi, Roya Kolahdouz ^a   Agah, Shahram ^a   Zarrati, Mitra ^a   Hosseini, Agha Fatemeh ^a   Arabshahi, Seyed Soroush Soltani ^a   Shidfar, Farzad ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Leptin; Lipid profile; Nonalcoholic fatty liver disease; Symbiotic; Vitamin E

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; LEPTIN; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; ECHOGRAPHY; FEMALE; FOLLOW UP; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 84994508649     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: 10.4103/1735-1995.193178     Document Type: Article

References (44)

1. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non alcoholic fatty liver disease and non alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
2. Angulo P. Long term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance? Hepatology 2010; 51: 373-5.
3. Jacobs M, van Greevenbroek MM, van der Kallen CJ, Ferreira I, Feskens EJ, Jansen EH, et al. The association between the metabolic syndrome and alanine amino transferase is mediated by insulin resistance via related metabolic intermediates (the Cohort on Diabetes and Atherosclerosis Maastricht [CODAM] study). Metabolism 2011; 60: 969-75.
4. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: The pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009; 9: 299-314.
5. Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic fatty liver disease: Multimodal treatment options for a pathogenetically multiple hit disease. J Clin Gastroenterol 2012; 46: 272-84.
6. Stankovic MN, Mladenovic DR, Duricic I, Šobajic SS, Timic J, Jorgacevic B, et al. Time dependent changes and association between liver free fatty acids, serum lipid profile and histological features in mice model of nonalcoholic fatty liver disease. Arch Med Res 2014; 45: 116-24.
7. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-31.
8. Rijkers GT, de Vos WM, Brummer RJ, Morelli L, Corthier G, Marteau P. Health benefits and health claims of probiotics: Bridging science and marketing. Br J Nutr 2011; 106: 1291-6.
9. Loguercio C, Federico A, Tuccillo C, Terracciano F, D’Auria MV, De Simone C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540-3.
10. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, et al. Bifidobacterium longum with fructo oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012; 57: 545-53.
11. Weltman MD, Farrell GC, Hall P, Ingelman Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-33.
12. Hill DB, Devalaraja R, Joshi Barve S, Barve S, McClain CJ. Antioxidants attenuate nuclear factor Kappa B activationand tumor necrosis factor alphaproduction in alcohol hepatitis patientmonocytes and rat kupffer cells, in vitro. Clin Biochem 1999; 32: 563-70.
13. Phung N, Pera N, Farrell G, Leclercq I, Hou JY, George J. Pro oxidant mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. Int J Mol Med 2009; 24: 171-80.
14. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011; 15: 1090-5.
15. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
17. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
18. Matsudo S, Araújo T, Matsudo V, Andrade D, Andrade E, Oliveira LC. International physical activity questionnaire (IPAQ): Validity and reproducibility in Brazil. Brazilian Journal of Physical Activity and Health 2001; 6: 5-18.
19. Eslamparast T, Eghtesad S, Hekmatdoost A, Poustchi H. Probiotics and Nonalcoholic Fatty liver disease. Middle East J Dig Dis 2013; 5: 129-36.
20. Baldwin AS Jr. The NF kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol 1996; 14: 649-83.
21. Biddinger SB, Hernandez Ono A, Rask Madsen C, Haas JT, Alemán JO, Suzuki R, et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 2008; 7: 125-34.
22. Yu AS, Keeffe EB. Elevated AST or ALT to nonalcoholic fatty liver disease: Accurate predictor of disease prevalence? Am J Gastroenterol 2003; 98: 955-6.
23. Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double blind, placebo controlled pilot study. Am J Clin Nutr 2014; 99: 535-42.
24. Malaguarnera M, Gargante MP, Malaguarnera G, Salmeri M, Mastrojeni S, Rampello L, et al. Bifidobacterium combined with fructo oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 2010; 22: 199-206.
25. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, Vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.
26. Sato K, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, et al. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: A meta analysis of randomized controlled trials. Nutrition 2015; 31: 923-30.
27. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012; 52: 59-69.
28. Pessayre D. Role of mitochondria in non alcoholic fatty liver disease. J Gastroenterol Hepatol 2007; 22 Suppl 1: S20-7.
29. Nan YM, Wu WJ, Fu N, Liang BL, Wang RQ, Li LX, et al. Antioxidants Vitamin E and 1 aminobenzotriazole prevent experimental non alcoholic steatohepatitis in mice. Scand J Gastroenterol 2009; 44: 1121-31.
30. Polyzos SA, Kountouras J, Zavos C, Stergiopoulos C. Adipocytokines in insulin resistance and non alcoholic fatty liver disease: The two sides of the same coin. Med Hypotheses 2010; 74: 1089-90.
31. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002; 37: 206-13.
32. Song MJ, Kim KH, Yoon JM, Kim JB. Activation of Toll like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 2006; 346: 739-45.
33. Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, et al. Serum adipokine levels predictive of liver injury in non alcoholic fatty liver disease. Liver Int 2009; 29: 1431-8.
34. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004; 41: 943-9.
35. Balmer ML, Siegrist K, Zimmermann A, Dufour JF. Effects of ursodeoxycholic acid in combination with Vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int 2009; 29: 1184-8.
36. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, et al. Toll like receptor 9 signaling mediates the anti inflammatory effects of probiotics in murine experimental colitis 2004; 126: 520-8.
37. Chatterjee S, Ganini D, Tokar EJ, Kumar A, Das S, Corbett J, et al. Leptin is key to peroxynitrite mediated oxidative stress and Kupffer cell activation in experimental non alcoholic steatohepatitis. J Hepatol 2013; 58: 778-84.
38. Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question. Nutr Metab Cardiovasc Dis 2007; 17: 684-98.
39. Foufelle F, Ferré P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: A role for the transcription factor sterol regulatory element binding protein 1c. Biochem J 2002; 366 (Pt 2): 377-91.
40. Akbarzadeh F, Homayouni A. Dairy probiotic foods and coronary heart disease: A review on mechanism of action. In: Rigobelo EC, editor. Probiotics. InTech; 2012. p. 121-8.
41. Yakaryilmaz F, Guliter S, Savas B, Erdem O, Ersoy R, Erden E, et al. Effects of Vitamin E treatment on peroxisome proliferator activated receptor alpha expression and insulin resistance in patients with non alcoholic steatohepatitis: Results of a pilot study. Intern Med J 2007; 37: 229-35.
42. Al Attas OS, Al Daghri NM, Al Rubeaan K, da Silva NF, Sabico SL, Kumar S, et al. Changes in endotoxin levels in T2DM subjects on anti diabetic therapies. Cardiovasc Diabetol 2009; 8: 20.
43. Cuoco L, Montalto M, Jorizzo RA, Santarelli L, Arancio F, Cammarota G, et al. Eradication of small intestinal bacterial overgrowth and oro cecal transit in diabetics. Hepatogastroenterology 2002; 49: 1582-6.
44. Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: Focus on molecular and biochemical mechanisms. J Nutr Biochem 2011; 22: 699-711.